Core Viewpoint - Yunding Xinyao announced the approval of its new drug, Weishiping® (Arginine Acquimod Tablets), in China for treating moderate to severe active ulcerative colitis in adults who have insufficient response to traditional therapies or biologics [1] Group 1: Drug Approval and Clinical Trials - The approval is based on the results of the Asian multicenter Phase III registration clinical trial ENLIGHTUC and the global Phase III registration study ELEVATEUC [1] - The ENLIGHTUC study included 340 patients and achieved statistical significance with good safety profiles during treatment [1] Group 2: Commercialization and Strategic Goals - The company will actively prepare for the commercialization of Weishiping® and aims to expedite its availability to domestic patients while promoting its inclusion in the national medical insurance catalog [1] - This approval is a key component of the company's 2030 development strategy, which emphasizes a dual approach of "BD cooperation + self-research" to achieve both commercialization and R&D value [1] - The company plans to exceed 10 billion RMB in revenue by 2028 and over 15 billion RMB by 2030, with a projected annual compound growth rate of over 50% from 2025 to 2030 [1]

Core Viewpoint - The company aims to achieve revenue exceeding 15 billion yuan by 2030, with a focus on both existing and new product pipelines [1] Group 1: Revenue Goals - The company plans to generate approximately 9 billion yuan from existing pipeline sales and around 6 billion yuan from newly introduced pipeline sales, while also exploring potential license-out revenue [1] Group 2: Product Pipeline Focus - The company will concentrate on core areas such as nephrology, autoimmune diseases, critical care, cardiovascular, and ophthalmology, aiming to develop a high-value product portfolio by 2030 [1] - The goal is to increase the number of commercialized products to over 20 by 2030 [1] Group 3: Strategic Approach - The company will adopt a dual approach of "BD collaboration + self-research" to drive growth, leveraging scientific insights and market understanding [1] - The company plans to introduce 3-5 mid-to-late stage blockbuster products annually through established BD capabilities and the Kangqiao ecosystem, aiming for peak sales within three years post-reimbursement for each product [1]

Core Viewpoint - The company has announced its 2030 development strategy, focusing on dual-driven growth through "BD collaboration + self-research" to enhance product pipelines and maximize commercial platform value [1][2]. Group 1: 2030 Development Strategy - The 2030 strategy outlines a five-year plan aimed at solidifying the company's core therapeutic areas and advancing innovative drug research and commercialization [1]. - The strategy emphasizes the importance of BD collaboration and self-research to create both certain and growth-oriented value [1][2]. - The company aims to introduce 3 to 5 late-stage significant products annually through established BD capabilities and partnerships, targeting peak sales within three years post-reimbursement [2]. Group 2: Shareholder Actions - Key executives and major shareholders have collectively increased their holdings by purchasing 846,700 shares for over HKD 38 million, averaging HKD 45.01 per share [1]. Group 3: Commercialization and Growth - The company has established a commercial system driven by scientific and market insights, which has led to significant sales growth, exemplified by a slow disease medication achieving over CNY 1 billion in sales in its first full commercial year [3]. - The company plans to leverage its commercialization experience in nephrology and anti-infection to expand into other therapeutic areas such as immunology, ophthalmology, critical care, and cardiovascular diseases [3]. - The company is committed to addressing unmet medical needs globally, enhancing its competitiveness in the innovative drug sector [3].